Table 1.
Correlation analysis of SRI expression and clinicopathological features in HCC patients.
| Characteristic | Low Expression of SRI | High Expression of SRI | p |
|---|---|---|---|
| T stage | 0.013 | ||
| T1 | 104 (28.3%) | 77 (20.9%) | |
| T2 | 37 (10.1%) | 57 (15.5%) | |
| T3 | 34 (9.2%) | 46 (12.5%) | |
| T4 | 8 (2.2%) | 5 (1.4%) | |
| N stage | 0.368 | ||
| N0 | 128 (50%) | 124 (48.4%) | |
| N1 | 1 (0.4%) | 3 (1.2%) | |
| M stage | 0.622 | ||
| M0 | 133 (49.3%) | 133 (49.3%) | |
| M1 | 3 (1.1%) | 1 (0.4%) | |
| Pathologic stage | 0.025 | ||
| Stage I | 98 (28.2%) | 73 (21%) | |
| Stage II | 37 (10.7%) | 49 (14.1%) | |
| Stage III | 36 (10.4%) | 49 (14.1%) | |
| Stage IV | 4 (1.2%) | 1 (0.3%) | |
| Tumor status | 0.018 | ||
| Tumor-free | 112 (31.8%) | 89 (25.3%) | |
| With tumor | 64 (18.2%) | 87 (24.7%) | |
| Gender | 0.53 | ||
| Female | 57 (15.4%) | 64 (17.3%) | |
| Male | 128 (34.5%) | 122 (32.9%) | |
| Age, n (%) | 1 | ||
| ≤60 | 89 (24.1%) | 88 (23.8%) | |
| >60 | 96 (25.9%) | 97 (26.2%) | |
| OS event | 0.042 | ||
| Alive | 130 (35%) | 111 (29.9%) | |
| Dead | 55 (14.8%) | 75 (20.2%) | |
| DSS event | 0.194 | ||
| Alive | 148 (40.8%) | 136 (37.5%) | |
| Dead | 34 (9.4%) | 45 (12.4%) | |
| Age, median (IQR) | 61 (51, 69) | 61 (52, 69) | 0.84 |